Physician profile
Collin Patrick Wurst
NPI 1144856634
$3,023.45
in general payments reported to CMS, 2019-2025
24 companies · $738 in 2025
The $738 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.60 · 2023: $1,008 · 2024: $1,180 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.85 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.82 | 2023-2025 | |
| Novo Nordisk INC | $591.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $300.41 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $260.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $197.44 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $145.83 | 2023-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $62.69 | 2023-2024 | Veozah |
| Smith+Nephew, INC. | $59.66 | 2025 | Pico |
| Merck Sharp & Dohme LLC | $55.86 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $52.87 | 2024-2025 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $50.53 | 2025 | |
| Edwards Lifesciences Corporation | $38.97 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.86 | 2022-2023 | Stiolto Respimat, Spiriva Respimat, Combivent Respimat |
| Pfizer INC. | $36.05 | 2023-2024 | |
| Exact Sciences Corporation | $27.32 | 2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.15 | 2025 | Camzyos |
| Endo USA, INC. | $21.59 | 2025 | Xiaflex |
| Dexcom, INC. | $21.51 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2024 | Xifaxan, Trulance |
| Kyowa Kirin, INC. | $17.85 | 2025 | |
| Seqirus USA INC | $17.73 | 2025 | Fluad, Flucelvax |
| Cumberland Pharmaceuticals, INC. | $16.71 | 2025 | Caldolor |
| Molnlycke Health Care US, LLC | $15.92 | 2025 | Mepilex Border Post-Op Ag, Mepilex Border Post-Op |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Wurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.